NerveLight (800-rhNGF)
Nerve imaging for prostatectomy (prostate cancer surgery)
Key Facts
About Manzanita Pharmaceuticals
Manzanita Pharmaceuticals is a private, pre-revenue biotech leveraging a proprietary platform to create neurotrophin-dye and neurotrophin-drug conjugates. Its primary focus is on developing NerveLight, a near-infrared (NIR) imaging agent for intraoperative nerve visualization, initially targeting prostatectomy to reduce complications like impotence and incontinence. Founded in 1982 (re-established in 2007), the company has been funded primarily through non-dilutive grants and angel investment, and is led by a small team with strong academic and entrepreneurial backgrounds. The technology platform promises applications beyond imaging, including novel drug delivery for pain and other neurological conditions.
View full company profile